Altimmune (ALT) Preferred Shares Issued (2016 - 2017)
Altimmune (ALT) reported Preferred Shares Issued of $13.0 million for Q3 2017, up 548.63% year-over-year from $2.0 million in Q3 2016, and up 548.63% quarter-over-quarter from $2.0 million in Q3 2016.
Altimmune (ALT) Preferred Shares Issued (2016 - 2017) Analysis & Trends
Altimmune (ALT) has 2 years of Preferred Shares Issued data on file, last reported at $13.0 million in Q3 2017.
- Preferred Shares Issued for Q3 2017 came in at $13.0 million, up 548.63% year-over-year; the trailing twelve-month figure through Dec 2017 was $15.0 million (changed N/A YoY), and the FY2017 annual result was $13.0 million, up 129.46% from the prior year.
- Preferred Shares Issued grew to $13.0 million in Q3 2017 per ALT's latest filing, from $2.0 million in the prior quarter.
- Over five years, Preferred Shares Issued peaked at $13.0 million in Q3 2017 and troughed at $2.0 million in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 12.97 Mn |
| Sep 30, 2017 | 12.97 Mn |
| Sep 30, 2016 | 2.00 Mn |
| Sep 30, 2016 | 2.00 Mn |